pharmacoeconom
decisionanalyt
model
incorpor
first
secondord
mont
carlo
simul
develop
investig
costeffect
costutil
healthi
adult
popul
year
perspect
healthcar
payer
uk
nation
health
servic
nh
societ
perspect
consid
cost
health
benefit
regardless
experi
purpos
analysi
usual
care
defin
symptomat
treatment
baselin
strategi
sinc
remain
standard
practic
influenza
treatment
despit
avail
altern
decis
tree
fig
visual
morbid
mortal
due
influenza
specifi
complic
model
start
gener
practition
gp
offic
sinc
oseltamivir
zanamivir
avail
gp
prescript
otc
medic
treatment
option
usual
care
current
practic
oseltamivir
intervent
zanamivir
intervent
effect
intervent
oseltamivir
zanamivir
achiev
addit
use
otc
medic
use
select
otc
medicin
paracetamol
antituss
allow
clinic
trial
disabl
symptom
model
distinguish
two
period
start
treatment
within
h
onset
symptom
h
well
influenzaposit
influenzaneg
case
diagnost
certainti
sinc
treatment
neuraminidas
inhibitor
confirm
effect
influenza
viru
taken
within
h
onset
symptom
cost
oseltamivir
zanamivir
treatment
incur
although
improv
health
outcom
infect
individu
probabl
influenzalik
ill
ili
develop
ilirel
complic
pneumonia
bronchiti
patient
without
complic
model
describ
three
diseas
state
outpati
symptomat
infect
result
outpati
treatment
primari
sector
inpati
symptomat
infect
result
hospit
includ
outpati
treatment
pre
posthospit
death
symptomat
infect
result
death
death
relat
ili
complic
includ
model
includ
outpati
inpati
treatment
death
diseas
state
appli
ili
case
ie
influenza
viru
posit
well
influenza
viru
neg
case
similar
branch
repres
plu
sign
model
structur
tabl
present
main
probabl
use
analysi
two
complic
includ
chosen
strong
associ
influenza
high
incid
applic
chosen
popul
group
model
assum
individu
develop
singl
complic
underli
data
epidemiolog
studi
provid
incid
complic
publish
inform
whether
individu
studi
popul
one
complic
time
assum
report
complic
occur
differ
patient
treatment
neuraminidas
inhibitor
assum
effect
incid
complic
cours
mean
baselin
usual
care
intervent
neuraminidas
inhibitor
probabl
hospit
mortal
due
bronchiti
pneumonia
complic
develop
due
limit
data
avail
assumpt
made
hospit
assum
bronchiti
mortal
rate
due
complic
lower
influenza
impact
uncertainti
surround
data
use
variabl
probabl
complic
hospit
mortal
determin
probabilist
sensit
analysi
secondord
mont
carlo
simul
recent
evid
clinic
practic
complianc
zanamivir
issu
particularli
elderli
patient
major
found
difficulti
load
devic
howev
clinic
trial
healthi
adult
popul
report
high
rate
complianc
therefor
complianc
zanamivir
assum
possibl
patient
discontinu
treatment
feel
better
develop
gastrointestin
side
effect
oseltamivir
treatment
alreadi
includ
underli
clinic
trial
data
intend
treat
popul
use
drug
side
effect
usual
mild
selflimit
ie
resourc
use
associ
impact
side
effect
qualiti
life
alreadi
includ
daili
qualiti
life
report
clinic
trial
studi
includ
assess
direct
medic
cost
healthcar
payer
perspect
also
product
loss
due
sick
leav
base
unit
cost
year
tabl
direct
healthcar
cost
use
model
includ
drug
use
cost
primari
secondari
care
resourc
cost
comprehens
unit
state
databas
nation
ambulatori
medic
care
survey
namc
use
develop
estim
resourc
use
complic
includ
gp
specialist
visit
test
investig
drug
data
level
detail
avail
specif
uk
namc
data
provid
rate
drug
prescrib
complic
well
drug
class
overal
rate
antibiot
prescrib
namc
databas
strikingli
similar
publish
estim
uk
exampl
meier
et
al
report
approx
complic
influenza
case
uk
treat
antibiot
namc
estim
uncompl
influenza
case
rate
respect
product
loss
valu
appli
human
capit
approach
thu
use
time
return
normal
activ
day
evalu
epidemiolog
studi
clinic
trial
valu
time
averag
gross
uk
incom
time
return
normal
activ
chosen
effect
measur
sinc
measur
meaning
patient
well
employ
decis
maker
allevi
fever
symptom
captur
part
diseas
pictur
return
normal
activ
measur
best
captur
cure
diseas
total
durat
ill
time
return
normal
activ
chosen
mortal
measur
effect
mortal
low
healthi
adult
therefor
endpoint
clinic
trial
healthi
adult
popul
main
goal
treat
healthi
adult
restor
patient
health
fast
possibl
furthermor
mortal
includ
qualiti
adjust
life
year
time
return
normal
activ
secondari
clinic
endpoint
oseltamivir
trial
measur
use
likerttyp
scale
endpoint
return
normal
activ
normal
activ
defin
usual
abil
carri
normal
activ
cours
depend
individu
hisher
interpret
healthi
adult
trial
patient
return
normal
activ
within
day
followup
period
treatment
start
howev
mean
restrict
mean
patient
return
normal
activ
last
trial
measur
mean
patient
return
normal
activ
within
day
censor
zanamivir
trial
howev
report
median
durat
day
return
normal
activ
day
placebo
vs
day
zanamivir
reduct
patient
record
symptom
temperatur
abil
perform
normal
daili
activ
diari
card
day
symptom
persist
day
avoid
death
improv
qualiti
life
given
singl
valu
use
approach
qualityadjust
lifeyear
qali
qualiti
weight
assign
health
state
adjust
time
patient
spend
state
qualiti
weight
valu
death
perfect
health
qualiti
weight
deriv
literatur
diseas
includ
analysi
influenza
bronchiti
pneumonia
sourc
use
ensur
consist
weight
gener
deriv
qualiti
weight
mean
also
consist
qualiti
weight
variou
diseas
heart
diseas
cancer
sinc
qualiti
life
vari
differ
treatment
option
influenza
result
clinic
trial
roch
use
estim
rel
improv
qualiti
life
placebo
oseltamivir
first
day
influenza
episod
approach
recent
nice
assess
use
improv
qualiti
life
placebo
oseltamivir
estim
patient
health
state
valuat
report
daili
day
oseltamivir
clinic
trial
qali
gener
recalibr
roch
likert
score
mean
vsual
analogu
scale
va
score
transform
time
tradeoff
equival
score
descript
transform
see
rel
improv
otherwis
healthi
adult
popul
appli
gener
influenza
qualiti
weight
deriv
qualiti
weight
ili
patient
effect
treat
oseltamivir
data
avail
qualiti
life
improv
zanamivir
improv
oseltamivir
assum
simul
patient
follow
model
individu
sinc
individu
patient
singl
state
given
time
pass
one
branch
tree
given
chanc
node
fig
henc
path
follow
differ
patient
differ
due
chanc
larg
number
patient
chosen
larg
number
endpoint
small
probabl
model
especi
mortal
individu
simul
method
estim
like
varianc
relat
simpli
inher
uncertainti
probabilist
structur
model
patient
variabl
secondord
montecarlo
simul
model
deal
uncertainti
relat
input
variabl
use
probabl
distribut
around
point
valu
mean
addit
allow
variabl
due
way
individu
travel
model
firstord
mont
carlo
simul
underli
model
variabl
allow
vari
given
rang
given
distribut
simul
run
valu
distribut
variabl
pick
random
gener
one
set
output
cost
effect
larg
number
simul
run
therefor
yield
distribut
output
possibl
impact
uncertainti
surround
certain
variabl
chosen
predefin
distribut
probabl
complic
hospit
mortal
durat
day
return
normal
activ
length
stay
hospit
beta
distribut
probabl
gamma
distribut
durat
use
patient
randomli
travers
singl
path
model
model
recalcul
time
increment
costeffect
costutil
analys
provid
addit
cost
addit
health
outcom
associ
scenario
compar
two
perspect
investig
healthcar
payer
societi
human
capit
approach
base
averag
incom
use
valu
patient
inabl
work
due
ill
avoid
doubl
count
costutil
analysi
indirect
cost
due
prematur
mortal
includ
sinc
captur
measur
health
outcom
qali
comparison
cost
also
exclud
costeffect
analysi
cost
effect
relat
influenza
occur
within
year
occur
futur
year
life
lost
due
prematur
death
therefor
result
analysi
present
discount
use
discount
rate
health
outcom
year
life
lost
per
annum
recommend
econom
evalu
healthcar
field
uk
base
case
defin
diagnost
certainti
rate
treatment
start
within
h
onset
symptom
oneway
sensit
analys
present
two
variabl
gener
believ
major
impact
result
diagnost
certainti
time
treatment
start
onset
symptom
diagnost
certainti
describ
percentag
influenzaposit
patient
within
ili
popul
presum
higher
influenza
circul
base
case
scenario
diagnost
certainti
assum
point
estim
assumpt
made
base
diagnost
certainti
rate
around
observ
oseltamivir
clinic
trial
draw
analys
publish
zanamivir
technolog
assess
chosen
low
estim
diagnost
certainti
sensit
analysi
sinc
time
treatment
start
within
h
onset
symptom
treatment
neuraminidas
inhibitor
effect
assumpt
made
patient
gp
consult
within
period
receiv
neuraminidas
inhibitor
sensit
analysi
impact
proport
patient
receiv
neuraminidas
inhibitor
h
symptom
evalu
clinic
trial
like
control
factor
alreadi
extent
howev
impact
patient
receiv
treatment
excess
h
symptom
onset
test
repres
arbitrari
proport
late
present
receiv
treatment
help
demonstr
sensit
result
variabl
multiway
sensit
analysi
assum
neuraminidas
inhibitor
effect
hospit
complic
mortal
low
diagnost
certainti
rate
perform
outcom
measur
includ
vari
degre
public
mean
effect
captur
reduct
day
return
normal
activ
improv
qualiti
life
typic
outpati
episod
influenza
addit
sensit
analysi
show
result
exclud
hospit
complic
mortal
strategi
usual
care
oseltamivir
zanamivir
diagnost
certainti
rate
life
year
lost
due
prematur
death
discount
discount
rate
therefor
expect
small
impact
result
howev
undiscount
analysi
perform
day
lost
time
return
normal
activ
valu
use
human
capit
approach
approach
reflect
valu
healthi
time
foregon
ie
also
valu
miss
leisur
time
time
return
normal
activ
use
base
case
analysi
seem
long
compar
studi
evalu
product
loss
sensit
analysi
therefor
perform
valu
product
loss
assum
outpati
time
return
normal
activ
product
loss
inpati
weekend
would
usual
ie
sick
leisur
time
therefor
work
loss
result
oneway
multiway
sensit
analys
present
comparison
oseltamivir
usual
care
sinc
zanamivir
domin
oseltamivir
sensit
analys
zanamivir
expens
oseltamivir
uk
two
neuraminidas
inhibitor
similar
way
action
effect
impact
lower
level
diagnost
certainti
upon
increment
costeffect
oseltamivir
compar
usual
care
see
tabl
nh
perspect
analys
demonstr
result
sensit
level
diagnost
certainti
assum
level
diagnost
certainti
reduc
increment
costeffect
ratio
oseltamivir
increas
also
seen
shift
costaccept
curv
right
see
fig
howev
oseltamivir
remain
costeffect
term
increment
cost
per
qali
gain
healthcar
payer
perspect
threshold
gain
domin
societ
perspect
even
assum
diagnost
certainti
impact
time
treatment
initi
costeffect
result
also
assess
tabl
base
case
assum
patient
treat
oseltamivir
start
treatment
within
h
symptom
onset
sensit
analysi
proport
late
starter
treatment
h
assum
societ
perspect
oseltamivir
still
domin
usual
care
healthcar
payer
perspect
oseltamivir
remain
costeffect
even
patient
receiv
benefit
influenza
neg
plu
late
present
among
influenza
posit
patient
multiway
sensit
analysi
omit
effect
relat
hospit
complic
mortal
assum
low
diagnost
certainti
rate
oseltamivir
still
cost
effect
nh
point
view
domin
usual
care
societ
point
view
expect
discount
small
impact
result
lower
work
loss
assum
sensit
analysi
influenza
uncomfort
condit
sever
affect
qualiti
life
rel
short
period
uncompl
selflimit
case
howev
review
literatur
suggest
actual
knowledg
influenza
consequ
health
healthcar
resourc
use
economi
limit
part
model
tri
captur
relev
publish
knowledg
diseas
implic
howev
context
decis
make
provid
treatment
neuraminidas
inhibitor
influenza
import
understand
result
present
condit
baselin
probabl
use
model
model
subject
number
limit
gener
lack
accur
inform
influenza
complic
mortal
hospit
rate
otherwis
healthi
adult
popul
baselin
probabl
influenza
complic
mortal
hospit
rather
public
due
rel
limit
knowledg
true
complic
mortal
rate
associ
influenza
also
worth
note
baselin
probabl
base
ili
confirm
influenza
case
possibl
filter
ili
case
due
pathogen
eg
respiratori
syncyti
viru
parainfluenzaviru
coronaviru
true
influenza
case
baselin
probabl
would
like
higher
despit
avail
rapid
influenza
test
test
routin
carri
costeffect
baselin
probabl
reflect
influenza
season
studi
conduct
interpandem
season
mean
case
particularli
strong
influenza
epidem
pandem
baselin
incid
rate
complic
mortal
hospit
would
probabl
substanti
higher
would
certainti
diagnosi
henc
result
costeffect
treatment
would
even
favor
assum
treatment
effect
due
data
limit
also
includ
hospit
due
bronchiti
includ
certain
secondari
complic
eg
asthmat
exacerb
cardiac
event
howev
exclus
event
model
like
gener
conserv
estim
benefit
influenza
treatment
analysi
also
limit
avail
accur
uk
medic
resourc
use
data
collect
alongsid
clinic
trial
estim
resourc
use
base
partli
upon
nonuk
resourc
data
combin
ukspecif
unit
cost
data
avail
base
upon
retrospect
analysi
patient
record
uk
inclus
data
namc
reflect
detail
breakdown
resourc
use
complic
similar
aggreg
data
resourc
use
compar
uk
sourc
hand
model
captur
much
influenza
ill
possibl
given
publish
data
use
probabilist
model
take
account
uncertainti
pertain
complic
hospit
mortal
rate
durat
day
return
normal
activ
length
stay
hospit
drive
dynam
influenza
influenza
treatment
patient
prefer
obtain
clinic
trial
use
rate
scale
oppos
standard
gambl
method
question
frame
certainti
subject
ask
perform
scale
task
base
introspect
therefor
rate
scale
method
requir
subject
choos
altern
captur
subject
risk
attitud
research
shown
standard
gambl
score
higher
time
tradeoff
score
higher
visual
analogu
score
bias
report
relat
rate
scale
endofscal
bia
subject
tend
use
end
scale
space
bia
subject
tend
space
outcom
scale
howev
rate
scale
method
wide
accept
method
measur
patient
prefer
quick
effici
furthermor
rate
scale
convert
time
tradeoff
score
use
powercurv
convers
day
normal
activ
gain
use
diseasespecif
outcom
enabl
us
make
comparison
intervent
consider
howev
interpret
result
straightforward
report
net
cost
day
normal
activ
gain
oseltamivir
compar
usual
care
otherwis
healthi
adult
gener
day
normal
activ
healthi
adult
popul
like
repres
good
valu
money
assum
earlier
return
work
averag
gross
daili
wage
approx
present
simul
result
use
mean
minimum
maximum
valu
costeffect
ratio
problem
relat
express
stochast
uncertainti
surround
costeffect
ratio
main
problem
discontinu
distribut
costeffect
ratio
sever
method
estim
confid
interv
costeffect
ratio
propos
pose
methodolog
challeng
one
altern
approach
use
accept
curv
also
present
analysi
assum
costeffect
ratio
symmetr
point
correspond
point
estim
costeffect
ratio
furthermor
curv
increas
monoton
cut
either
end
vertic
axi
use
curv
map
valu
horizont
axi
defin
confid
interv
howev
limit
method
prefer
gain
loss
fact
symmetr
ie
point
would
correspond
mean
valu
increment
costeffect
ratio
import
consid
result
context
publish
costeffect
analys
influenza
treatment
uk
analys
present
recent
guidanc
regard
use
oseltamivir
zanamivir
amantadin
nice
report
increment
cost
per
qali
oseltamivir
zanamivir
amantadin
compar
usual
care
base
case
assum
diagnost
certainti
impact
hospit
mortal
otherwis
healthi
adult
popul
sensit
analysi
altern
model
specif
diagnost
certainti
show
follow
increment
cost
per
qali
compar
usual
care
amantadin
oseltamivir
zanamivir
compar
result
present
studi
given
present
publish
knowledg
influenza
diseas
associ
complic
analysi
found
oseltamivir
costeffect
treatment
influenza
compar
usual
care
zanamivir
otherwis
healthi
adult
popul
increment
costeffect
ratio
compar
oseltamivir
usual
care
per
day
activ
gain
health
care
payer
perspect
probabilist
model
use
explor
uncertainti
around
base
case
mean
expect
costeffect
ratio
demonstr
simul
estim
consist
conclus
oseltamivir
costeffect
popul
group
evalu
societ
perspect
treatment
oseltamivir
domin
usual
care
zanamivir
provid
health
benefit
lower
total
cost
